AMENDMENTS TO THE CLAIMS

1-48. (canceled)

49. (currently amended): An isolated or recombinant polypeptide having SEQ ID NO: 3[[, 5,]] or 7.

50-56. (canceled)

57. (previously presented): A composition which comprises the polypeptide of claim 49 and a pharmaceutically acceptable carrier.

58. (currently amended): A method of generating an immune response in a mammalian subject comprising exposing cells of the mammal's immune system to a polypeptide having SEQ ID NO: 3[[, 5,]] or 7, whereby an immune response to the polypeptide is generated, and wherein said immune response is the activation of B cells.

59-62. (canceled)

63. (currently amended): A polynucleotide that encodes the polypeptide of claim 49 ~~or is fully complementary to the polynucleotide~~ wherein T can also be U.

64-65. (canceled)

66. (currently amended): [[The]]A polynucleotide ~~of claim 63~~ having SEQ ID NO: 2[[, 4,]] or 6, wherein the polynucleotide encodes an isolated or recombinant polypeptide having SEQ ID NO: 3 or 7.

67-71. (canceled)

72. (previously presented): An isolated host cell modified to contain an expression vector for expressing the polynucleotide of claim 63.

73-74. (canceled)

75. (currently amended): A method for detecting the presence of prostate cancer expressing a 254P1D6B protein in an individual comprising:

determining the level of expression of a polypeptide having SEQ ID NO: 3[[, 5,]] or 7 in a test tissue sample from an individual; wherein the test tissue sample ~~is selected from the group consisting~~ consists of ~~lung, ovary, breast, pancreas, and~~ prostate tissue; and

comparing the level so determined to the level of expression that is evidenced in a normal tissue sample,

wherein the elevated expression of said polypeptide in the test tissue sample versus the normal tissue sample is an indication of the presence of cancer in the test tissue sample.

76-80. (canceled)